The AspireAssist is implanted in a 15-minute outpatient procedure, is fully reversible, and does not alter the patient’s internal anatomy. After 52-weeks of therapy, patients lost 37% of their excess weight, on average. Although the study was not sized to show significant improvement in cardiometabolic parameters, clinically significant improvement in the treatment group was seen in HbA1C (-0.36% relative to 5.7% baseline, P <0.0001), triglycerides (−9.9%, P =0.02), and high-density lipoprotein cholesterol (+8.1%, P =0.0001), at week 52 compared with baseline. There was no evidence of patients in the treatment group developing adverse eating behaviors.
“Patients with AspireAssist therapy have the opportunity not only to lose a significant amount of weight in a safe and controlled manner, but also to develop a healthier life style through more mindful eating habits,” said Louis Aronne, MD, FACP, the Sanford I. Weill Professor of Metabolic Research at Weill-Cornell Medicine and a co-Principal Investigator of the PATHWAY study.
“With less than 1% of the 29 million Americans with BMIs over 35 availing themselves of bariatric surgery each year, there is a significant unmet need for a non-surgical weight loss procedure that is effective, safe, and reversible. AspireAssist therapy satisfies this need and additionally offers a lower cost solution to the healthcare system. Publication of the PATHWAY results should help facilitate insurance coverage,” said Katherine Crothall, PhD, President & CEO of Aspire Bariatrics.
The full text publication can be accessed online or download the full-text PDF.
About Aspire Bariatrics, Inc.
Aspire is a committed to providing safe and effective treatments for obesity to patients worldwide, with excellent customer service, education, and continued innovation. www.aspirebariatrics.com.
Statements in this press release that are not historical facts are forward-looking statements and are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact for Investors and Media
Kathy Crothall, PhD
President and CEO